Physician profile
John C Lepage
NPI 1871511188
$3,533.56
in general payments reported to CMS, 2019-2025
23 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2021: $191 · 2022: $707 · 2023: $725 · 2024: $1,239 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.04 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.52 | 2019-2024 | |
| Janssen Biotech, INC. | $407.91 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $287.82 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.84 | 2022-2025 | Spevigo, Cyltezo |
| Ucb, INC. | $241.13 | 2021-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $210.59 | 2022-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $190.35 | 2022-2025 | Absorica Ld, Winlevi |
| Journey Medical Corporation | $180.82 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $176.65 | 2019-2023 | Dupixent |
| Galderma Laboratories, L.P. | $136.56 | 2024 | |
| Janssen Scientific Affairs, LLC | $109.99 | 2019 | |
| Dermira, INC. | $97.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.99 | 2023-2024 | Cabtreo, Arazlo |
| Novartis Pharmaceuticals Corporation | $83.02 | 2019-2024 | |
| Genzyme Corporation | $75.69 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $70.30 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $49.34 | 2019-2023 | |
| Krystal Biotech INC | $18.94 | 2023 | Vyjuvek |
| Arcutis Biotherapeutics, INC. | $17.60 | 2025 | Zoryve |
| Pfizer INC. | $16.02 | 2021 | |
| Vyne Pharmaceuticals INC. | $14.93 | 2021 | |
| Sandoz INC. | $14.92 | 2024 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lepage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.